{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T22:06:03Z","timestamp":1748469963188,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,4,16]],"date-time":"2016-04-16T00:00:00Z","timestamp":1460764800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s00280-016-3000-3","type":"journal-article","created":{"date-parts":[[2016,4,16]],"date-time":"2016-04-16T14:25:41Z","timestamp":1460816741000},"page":"1097-1102","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer"],"prefix":"10.1007","volume":"77","author":[{"given":"Rabih","family":"Said","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Kakadiaris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarina","family":"Piha-Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siqing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Falchook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filip","family":"Janku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer J.","family":"Wheler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"Zinner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apostolia M.","family":"Tsimberidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,16]]},"reference":[{"key":"3000_CR1","unstructured":"http:\/\/www.fda.gov\/downloads\/drugs\/drugsafety\/ucm111335.pdf . 2014"},{"key":"3000_CR2","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0960-894X(99)00250-4","volume":"9","author":"GW Muller","year":"1999","unstructured":"Muller GW, Chen R, Huang SY et al (1999) Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 9:1625\u20131630","journal-title":"Bioorg Med Chem Lett"},{"key":"3000_CR3","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","volume":"163","author":"LG Corral","year":"1999","unstructured":"Corral LG, Haslett PA, Muller GW et al (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163:380\u2013386","journal-title":"J Immunol"},{"key":"3000_CR4","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMp068087","volume":"355","author":"AH Sharpe","year":"2006","unstructured":"Sharpe AH, Abbas AK (2006) T-cell costimulation\u2014biology, therapeutic potential, and challenges. N Engl J Med 355:973\u2013975","journal-title":"N Engl J Med"},{"key":"3000_CR5","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s00280-012-1874-2","volume":"69","author":"A Segler","year":"2012","unstructured":"Segler A, Tsimberidou AM (2012) Lenalidomide in solid tumors. Cancer Chemother Pharmacol 69:1393\u20131406","journal-title":"Cancer Chemother Pharmacol"},{"key":"3000_CR6","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.mvr.2005.01.002","volume":"69","author":"K Dredge","year":"2005","unstructured":"Dredge K, Horsfall R, Robinson SP et al (2005) Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 69:56\u201363","journal-title":"Microvasc Res"},{"key":"3000_CR7","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara N, Hillan KJ, Gerber HP et al (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391\u2013400","journal-title":"Nat Rev Drug Discov"},{"key":"3000_CR8","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s40265-014-0302-9","volume":"74","author":"GM Keating","year":"2014","unstructured":"Keating GM (2014) Bevacizumab: a review of its use in advanced cancer. Drugs 74:1891\u20131925","journal-title":"Drugs"},{"key":"3000_CR9","unstructured":"http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/125085s263lbl.pdf . 2013"},{"key":"3000_CR10","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10637-013-9966-3","volume":"32","author":"P Ganesan","year":"2014","unstructured":"Ganesan P, Piha-Paul S, Naing A et al (2014) Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. Invest New Drugs 32:279\u2013286","journal-title":"Invest New Drugs"},{"key":"3000_CR11","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s10637-013-0013-1","volume":"31","author":"P Ganesan","year":"2013","unstructured":"Ganesan P, Piha-Paul S, Naing A et al (2013) Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer. Invest New Drugs 31:1505\u20131513","journal-title":"Invest New Drugs"},{"key":"3000_CR12","unstructured":"Common Terminology Criteria for Adverse Events v3.0 (CTCAE). National Cancer Institute (2006). http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf . Accessed 18 Dec 2012"},{"key":"3000_CR13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"3000_CR14","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/j.ejca.2006.05.018","volume":"42","author":"RA Sharma","year":"2006","unstructured":"Sharma RA, Steward WP, Daines CA et al (2006) Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies. Eur J Cancer 42:2318\u20132325","journal-title":"Eur J Cancer"},{"key":"3000_CR15","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/01.cad.0000231481.07654.fc","volume":"17","author":"V Gotlib","year":"2006","unstructured":"Gotlib V, Khaled S, Lapko I et al (2006) Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. Anticancer Drugs 17:1227\u20131229","journal-title":"Anticancer Drugs"},{"key":"3000_CR16","first-page":"129","volume":"3","author":"ID Ladas","year":"2009","unstructured":"Ladas ID, Moschos MM, Papakostas TD et al (2009) Skin rash associated with intravitreal bevacizumab in a patient with macular choroidal neovascularization. Clin Ophthalmol 3:129\u2013131","journal-title":"Clin Ophthalmol"},{"key":"3000_CR17","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","volume":"106","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar SV, Hayman SR, Lacy MQ et al (2005) Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma. Blood 106:4050\u20134053","journal-title":"Blood"},{"key":"3000_CR18","unstructured":"http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/021880s034lbl.pdf . 2013"},{"key":"3000_CR19","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/cncr.24686","volume":"116","author":"T Eisen","year":"2010","unstructured":"Eisen T, Trefzer U, Hamilton A et al (2010) Results of a multicenter, randomized, double-blind phase 2\/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer 116:146\u2013154","journal-title":"Cancer"},{"key":"3000_CR20","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1002\/cncr.24576","volume":"115","author":"J Glaspy","year":"2009","unstructured":"Glaspy J, Atkins MB, Richards JM et al (2009) Results of a multicenter, randomized, double-blind, dose-evaluating phase 2\/3 study of lenalidomide in the treatment of metastatic malignant melanoma. Cancer 115:5228\u20135236","journal-title":"Cancer"},{"key":"3000_CR21","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/COC.0b013e31815e451f","volume":"31","author":"RJ Amato","year":"2008","unstructured":"Amato RJ, Hernandez-McClain J, Saxena S et al (2008) Lenalidomide therapy for metastatic renal cell carcinoma. Am J Clin Oncol 31:244\u2013249","journal-title":"Am J Clin Oncol"},{"key":"3000_CR22","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1002\/cncr.22290","volume":"107","author":"TK Choueiri","year":"2006","unstructured":"Choueiri TK, Dreicer R, Rini BI et al (2006) Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer 107:2609\u20132616","journal-title":"Cancer"},{"key":"3000_CR23","unstructured":"Callander NS, Markovina S, Juckett MB, Wagner E et al. (2009) The addition of bevacizumab (B) to lenalidomide and low dose dexamethasone does not significantly increase response in relapsed or refractory multiple myeloma. https:\/\/ash.confex.com\/ash\/2009\/webprogram\/Paper18402.html"},{"key":"3000_CR24","doi-asserted-by":"crossref","unstructured":"Adesunloye B, Huang X, Ning YM, Madan RA et al. (2012) Dual antiangiogenic therapy using lenalidomide and bevacizumab with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 30, (suppl; abstr 4569)","DOI":"10.1200\/jco.2012.30.15_suppl.4569"},{"key":"3000_CR25","doi-asserted-by":"crossref","unstructured":"Adesunloye B, Huang X, Ning YM, Madan RA et al. (2012) Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 30(suppl 5; abstr 207)","DOI":"10.1200\/jco.2012.30.5_suppl.207"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3000-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-016-3000-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3000-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T20:17:34Z","timestamp":1718482654000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-016-3000-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,16]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["3000"],"URL":"https:\/\/doi.org\/10.1007\/s00280-016-3000-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2016,4,16]]}}}